(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
International Journal of Molecular Sciences · 20.06.2024 · 25 (12) · 6804
DOI: 10.3390/ijms25126804 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.06.2024. Verfasst von Hana Shafique und 7 weiteren Autor:innen. Beteiligte Einrichtung: Duke University School of Medicine, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Ketamine, Antidepressive Agents, Nervous System Diseases, Receptors, N-Methyl-D-Aspartate. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative diseases, epilepsy, traumatic brain injury, substance abuse disorder (SUD), and major depressive disorder (MDD). (S)-ketamine was the first of a novel class of antidepressants, rapid-acting antidepressants, to be approved for medical use. The stereoisomer, (R)-ketamine (arketamine), is currently under development for treatment-resistant depression (TRD). The compound has demonstrated efficacy in multiple animal models. Two clinical studies disclosed efficacy in TRD and bipolar depression. A study by the drug sponsor recently failed to reach a priori clinical endpoints but post hoc analysis revealed efficacy. The clinical value of (R)-ketamine is supported by experimental data in humans and rodents, showing that it is less sedating, does not produce marked psychotomimetic or dissociative effects, has less abuse potential than (S)-ketamine, and produces efficacy in animal models of a range of neurological and psychiatric disorders. The mechanisms of action of the antidepressant effects of (R)-ketamine are hypothesized to be due to NMDA receptor antagonism and/or non-NMDA receptor mechanisms. We suggest that further clinical experimentation with (R)-ketamine will create novel and improved medicines for some of the neurological and psychiatric disorders that are underserved by current medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke University School of Medicine, Durham, NC 27710, USA.
- Indiana University-Purdue University, Indianapolis, IN 46202, USA.
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
- Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent Hospital, Indianapolis, IN 46260, USA.
- Department of Psychology, SWPS University, 03-815 Warsaw, Poland.
- Departments of Neuroscience and Trauma Research, Ascension St. Vincent Hospital, Indianapolis, IN 46260, USA.
ORCID-Profile: Lalit K Golani
Zitieren
APA
Shafique, H., Demers, J. C., Biesiada, J., Golani, L. K., Cerne, R., Smith, J. L., Szostak, M., & Witkin, J. M. (2024). (R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders. International Journal of Molecular Sciences, 25(12), 6804. https://doi.org/10.3390/ijms25126804
Vancouver
Shafique H, Demers JC, Biesiada J, Golani LK, Cerne R, Smith JL, et al. (R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders. International Journal of Molecular Sciences. 2024;25(12):6804. doi:10.3390/ijms25126804
BibTeX
@article{Shafique2024,
author = {Shafique, Hana and Demers, Julie C and Biesiada, Julia and Golani, Lalit K and Cerne, Rok and Smith, Jodi L and Szostak, Marta and Witkin, Jeffrey M},
title = {(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {12},
pages = {6804},
doi = {10.3390/ijms25126804}
}
EUVIMED